This finding is particularly significant as it demonstrates that the cardiovascular benefits of GLP-1 agonists extend beyond their glucose-lowering effects to encompass direct cardiovascular protection in obesity
This blog post explores this topic in more detail For our mainstream media analysis, we used Onclusives media monitoring tool to focus on seven major brands and their CEOs from our report: Danone Diageo Glanbia Mondelez International Nestl PepsiCo GLP-1 & Food & Beverage Brands Media Mentions Over Time Onclusives media monitoring tool revealed that between April 1 and July 11, 2024, there were 3,610 mainstream media mentions of GLP-1 in connection with the seven brands analyzed
Strategies for managing this period include maintaining close communication with your healthcare provider about side effects, using all available anti-nausea strategies proactively rather than reactively, accepting that some temporary discomfort accompanies effective treatment, focusing on the progress already made rather than the challenges remaining, and remembering that 85% of patients report minimal side effects by month four
Future discoveries may lead to a new group of obesity treatments based on probiotics, devise ways to detect developing obesity, and allow effective prevention